Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Lixte Biotechnology Holdings, Inc.    LIXT

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(LIXT)
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Lixte Biotechnology : LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2019 | 04:38am EDT

Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the opening of a pharmacologic study of the ability of its lead clinical compound, LB-100, to enter the brain and penetrate recurrent glioblastoma multiforme tumors in patients in which surgical removal of their cancers is indicated (clinical trials registry: NCT03027388). The study is being conducted by the National Cancer Institute under a Cooperative Research and Development Agreement (CRADA) with Lixte.

Dr. John S. Kovach, founder and CEO of Lixte, said, Glioblastoma brain tumors (GBMs) are very challenging to treat. Radiation combined with the chemotherapeutic drug, temozolomide has been the mainstay of GBM therapy for decades with some further benefit gained by the addition of one or more anti-cancer drugs but without major advances in overall survival for the majority of patients. In animal models of GBM, Lixtes novel protein phosphatase inhibitor, LB-100, enhances the effectiveness of radiation, temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain is not known. Unfortunately, many drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.

The NCI study is designed to determine the extent to which LB-100 enters recurrent GBMs and related brain tumors. Patients having surgery to remove one or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed for the amount of LB-100 present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular target. The goal is to obtain data in up to eight patients. Thanks to the innovative design of the NCI study, data from so few patients should be sufficient to provide a sound rationale for a conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs.

(c) 2019 Future Publishing Limited Quay House, The Ambury, Bath BA1 1UA. All rights reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LIXTE BIOTECHNOLOGY HOLDIN
08/06LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
08/06LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Entry into a Material Definitive Agreement,..
AQ
08/06The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Abi..
GL
07/18First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in..
GL
06/26LIXTE BIOTECHNOLOGY : Biotechnologys PP2A Inhibitor, LB-100, Improves Brain Func..
AQ
06/25Lixte Biotechnology's PP2A Inhibitor, LB-100, Improves Brain Function and Mot..
GL
05/17LIXTE BIOTECHNOLOGY : LB-100 to be Evaluated by the National Cancer Institute in..
AQ
05/15LIXTE BIOTECHNOLOGY : LB-100 to be Evaluated by the National Cancer Institute in..
AQ
05/09LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
03/25LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
More news
Chart LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Duration : Period :
Lixte Biotechnology Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
John S. Kovach President, CEO, CFO, Director
Philip F. Palmedo Independent Director
Stephen J. Forman Director
Yun Yen Director
Sze Chun Ho Director
Sector and Competitors
1st jan.Capitalization (M$)
LIXTE BIOTECHNOLOGY HOLDINGS, INC.12.84%86
IQVIA HOLDINGS INC.22.98%27 985
LONZA GROUP35.49%25 918
CELLTRION, INC.--.--%20 866
INCYTE CORPORATION23.46%16 885
SEATTLE GENETICS, INC.74.09%16 762